Bolao Ignacio García, Calvo Naiara, Macias Alfonso, Barba Joaquin, Salterain Nahikari, Ramos Pablo, Ballesteros Gabriel, Neglia Renzo
Clinica Universidad de Navarra. Pamplona, Spain.
J Atr Fibrillation. 2016 Feb 29;8(5):1346. doi: 10.4022/jafib.1346. eCollection 2016 Feb-Mar.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and is associated with a fivefold increase in the risk of ischemic stroke and systemic embolism. Left atrial appendage (LAA) is the source of thrombi in up to 90% of patients with nonvalvular atrial fibrillation (AF). Although thromboembolic prophylaxis by means of oral anticoagulants (OAC) has been shown to be very effective (OAC), they also confer an inevitably risk of serious bleeding. Catheter ablation (CA) is an effective treatment for symptomatic AF but its role in stroke prevention remains unproved. Recently, LAA percutaneous occlusion has been demonstrated to be equivalent to OACs in reducing thromboembolic events. The aim of this review is to describe the rationale, feasibility, outcomes and technique of a combined procedure of AFCA and percutaneous LAAO, two percutaneous interventions that share some procedural issues and technical requirements, in patients with symptomatic drug-refractory AF, high risk of stroke, and contraindications to OACs.
心房颤动(AF)是最常见的持续性心律失常,与缺血性中风和全身性栓塞风险增加五倍相关。在高达90%的非瓣膜性心房颤动(AF)患者中,左心耳(LAA)是血栓的来源。尽管口服抗凝剂(OAC)预防血栓栓塞已被证明非常有效,但它们也不可避免地带来严重出血风险。导管消融(CA)是治疗症状性AF的有效方法,但其在预防中风方面的作用仍未得到证实。最近,经皮封堵LAA在减少血栓栓塞事件方面已被证明与OAC相当。本综述的目的是描述在有症状的药物难治性AF、中风高危和OAC禁忌证的患者中,AFCA与经皮LAAO联合手术的基本原理、可行性、结果和技术,这两种经皮干预措施存在一些共同的操作问题和技术要求。